Introducing a new generation of prognostic precision in breast cancer

EndoPredict is a genomic test for people newly diagnosed with early-stage, estrogen-receptor-positive, HER2-negative breast cancer. Research shows that the EndoPredict test may be widely used to help make treatment decisions based on the cancer’s risk of coming back in a part of the body away from the breast (distant metastasis) within 10 years after diagnosis. EndoPredict provides a risk score that is either low-risk or high-risk of breast cancer recurring as distant metastasis. Knowing if the cancer has a high or low risk of recurrence can help women and their doctors decide if chemotherapy or other treatments to reduce risk after surgery are needed.

Learn More

Recommended Links